Jia Wenqing, Xu Chengling, Zhao Tong, Fan Qiuyang, Qiao Bo, Wu Yueying, Yuan Jiali, Chen Jing
School of Basic Medical Science, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
School of Chinese Medical Science, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Evid Based Complement Alternat Med. 2023 Jan 3;2023:1130893. doi: 10.1155/2023/1130893. eCollection 2023.
BACKGROUND: Asthma is a chronic inflammatory disease of the airways with recurrent attacks, which seriously affects the patients' quality of life and even threatens their lives. The disease can even threaten the lives of patients. Sijunzi decoction (SJZD), a classical Chinese medicine formula with a long history of administration, is a basic formula used for the treatment of asthma and demonstrates remarkable efficacy. However, the underlying mechanism has not been elucidated. MATERIALS AND METHODS: We aimed to integrate network pharmacology and intestinal flora sequencing analysis to study the mechanism of SJZD in the treatment of allergic asthmatic mice. The active compounds of SJZD and their asthma-related targets were predicted by various databases. We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses to identify potentially relevant pathways for target genes. Furthermore, the active compound-target and target-signaling pathway network maps were constructed by using Cytoscape 3.8.2. These results were combined with those of the intestinal flora sequencing analysis to study the influence of SJZD on airway inflammation in allergic asthmatic mice. RESULT: We obtained 137 active compounds from SJZD and associated them with 1445 asthma-related targets acquired from the databases. A total of 109 common targets were identified. We visualized active compound-target and target-signaling pathway network maps. The pathological analysis and inflammation score results suggested that SJZD could alleviate airway inflammation in asthmatic mice. Sequencing analysis of intestinal flora showed that SJZD could increase the relevant abundance of beneficial bacterial genus and maintain the balance of the intestinal flora. The core toll-like receptor (TLR) signaling pathway was identified based on network pharmacology analysis, and the important role TLRs play in intestinal flora and organismal immunity was also recognized. The analysis of the correlation between environmental factors and intestinal flora revealed that beneficial bacterial genera were negatively correlated with TLR2 and positively correlated with the TLR7 expression. Furthermore, they were positively correlated with IFN- and IL-10 levels and negatively correlated with IL-4 and IL-17 levels. CONCLUSION: SJZD alleviated the airway inflammation state in asthmatic mice. The findings suggest that increasing the relevant abundance of beneficial intestinal bacteria in mice with asthma, regulating intestinal flora, interfering with the level of TLR2 and TLR7 expression to adjust the secretion of inflammatory factors, and alleviating asthmatic airway inflammation may be the possible mechanism involved in the treatment of asthma by SJZD, providing a basis for further studies on SJZD.
背景:哮喘是一种气道慢性炎症性疾病,反复发作,严重影响患者生活质量,甚至威胁生命。四君子汤(SJZD)是一种应用历史悠久的经典中药方剂,是治疗哮喘的基础方剂,疗效显著。然而,其潜在机制尚未阐明。 材料与方法:我们旨在整合网络药理学和肠道菌群测序分析,以研究SJZD治疗过敏性哮喘小鼠的机制。通过各种数据库预测SJZD的活性成分及其哮喘相关靶点。我们进行了基因本体论(GO)和京都基因与基因组百科全书(KEGG)分析,以确定靶基因潜在的相关途径。此外,使用Cytoscape 3.8.2构建活性成分-靶点和靶点-信号通路网络图谱。将这些结果与肠道菌群测序分析结果相结合,研究SJZD对过敏性哮喘小鼠气道炎症的影响。 结果:我们从SJZD中获得了137种活性成分,并将它们与从数据库中获取的1445个哮喘相关靶点相关联。共鉴定出109个共同靶点。我们可视化了活性成分-靶点和靶点-信号通路网络图谱。病理分析和炎症评分结果表明,SJZD可减轻哮喘小鼠的气道炎症。肠道菌群测序分析表明,SJZD可增加有益菌属的相关丰度,维持肠道菌群平衡。基于网络药理学分析确定了核心Toll样受体(TLR)信号通路,并认识到TLR在肠道菌群和机体免疫中的重要作用。环境因素与肠道菌群相关性分析表明,有益菌属与TLR2呈负相关,与TLR7表达呈正相关。此外,它们与IFN-和IL-10水平呈正相关,与IL-4和IL-17水平呈负相关。 结论:SJZD减轻了哮喘小鼠的气道炎症状态。研究结果表明,增加哮喘小鼠肠道有益菌的相关丰度、调节肠道菌群、干扰TLR2和TLR7表达水平以调节炎症因子分泌、减轻哮喘气道炎症可能是SJZD治疗哮喘的潜在机制,为进一步研究SJZD提供了依据。
Evid Based Complement Alternat Med. 2022-4-12
BMC Complement Med Ther. 2023-12-13
Zhongguo Zhong Yao Za Zhi. 2020-11
Arch Microbiol. 2022-11-28
Microorganisms. 2022-10-19
Inflammopharmacology. 2022-12
Allergol Int. 2023-1